Tenofovir-related nephropathies in HIV-infected patients

Current Vascular Pharmacology

Volumn 13, Issue 5, 2015, Pages 670-675

  Lai, Silvia ^a   Mariotti, Amalia ^a   Lai, Carlo ^b   Testorio, Massimo ^a   Carta, Maria ^a   Innico, Georgie ^a   Frassetti, Nicla ^a   Mangiulli, Marco ^a   D’Angelo, Annarita ^a   Russo, Gaspare E ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Highly active antiretroviral therapy; Human immunodeficiency virus; Kidney disease; Tenofovir disoproxil fumarate

Indexed keywords

CREATININE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ELECTROLYTE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; MALE; MIDDLE AGED; PHOSPHATURIA; POLYMERASE CHAIN REACTION; PROTEINURIA; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; KIDNEY FUNCTION TEST; PROCEDURES;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROTEINURIA; TENOFOVIR;

EID: 84940920803     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666141120131850     Document Type: Article

References (43)

1. Lopes JA, Melo MJ, Raimundo M, Fragoso A, Antunes F. Longterm risk of mortality for acute kidney injury in HIV-infected patients: a cohort analysis. BMC Nephrol 2013; 14: 32.
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362(9377): 22-9.
3. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6(2): 99-106.
4. Sabin C. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS 2002; 16 (Suppl 4): S61-8.
5. Palella FJ Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43(1): 27-34.
6. Röling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIVassociated renal diseases and highly active antiretroviral therapyinduced nephropathy. Clin Infect Dis 2006; 42(10): 1488-95.
7. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9(2): 72-81.
8. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16(8): 2412-20.
9. Fine DM, Perazella MA, Lucas GM, Atta MG. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs 2008; 68 (7): 963-80.
10. Daugas E, Rougier JP, Hill G. Haart-related nephropathies in HIVinfected patients. Kidney Int 2005; 67(2): 393-403
11. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22(2): 99-103.
12. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21(10): 1273-81.
13. Gallant JE1, Moore RD. Renal function with use of a tenofovircontaining initial antiretroviral regimen. AIDS 2009; 23(15): 1971- 5.
14. Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48(11): e108-16.
15. Rodríguez-Nóvoa S, Labarga P, D'avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010; 24(7): 1064-6.
16. Coca S, Perazella MA. Rapid communication: Acute renal failure associated with tenofovir; evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324(6): 342-4.
17. Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV- 1-positive patient treated with tenofovir. AIDS 2003; 17(6): 935-7.
18. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Druginduced Fanconi's syndrome. Am J Kidney Dis 2003; 41(2): 292- 309.
19. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1- infected patients. data from a double-blind randomized activecontrolled multicentre study. Nephrol Dial Transplant 2005; 20(4): 743-6.
20. Mateo L, Holgado S, Mariñoso ML, et al. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol 2014 May 3. [Epub ahead of print]
21. Koenig KF, Kalbermatter S, Menter T, Graber P, Kiss D. Recurrent bone fractures due to tenofovir-induced renal phosphate wasting. Scand J Infect Dis 2014; 46(3): 221-4
22. Levey AS. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53(4): 766-72.
23. Gupta S, Eustace AC, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients. Recommendations of the HIV Medicine Association of the Infectious Disease Society of America. Clin Infect Dis 2005; 40(11): 1559-85.
24. Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61(1): 195-202.
25. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39(8): 1199-206.
26. Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004; 61(1): 1- 6.
27. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66(3): 1145-52.
28. Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir. a pharmacogenetic study. Clin Infect Dis 2009; 48(11): e108-16.
29. Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA. Mitochondrial tubulopathy in tenofovir disoproxil fumarate treated rats. J Acquir Immune Defic Syndr 2009; 51(3): 258-63.
30. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346(11): 811-20.
31. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? N Engl J Med 2002; 346(11): 811-20.
32. Martin M, Vanichseni S, Suntharasamai P, et al. Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012. Clin Infect Dis 2014; 59(5): 716-24.
33. Young J, Wang Q, Fux C, et al. The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Med 2014; 15(8): 505-10.
34. Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int 2010; 78(5): 478-85.
35. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78(11): 1171-7.
36. Ramadhani HO, Bartlett JA, Thielman NM, et al. Association of first-line antiretroviral therapy adherence with adherence to second- line antiretroviral therapy among HIV-infected Patients in Tanzania. Open Forum Infect Dis 2014; 1(2): (Oxford Journals).
37. Oboho I, Abraham AG, Benning L, et al. Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2013; 62(4): 388-95.
38. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354(23): 2473-83.
39. Bickel M, Khaykin P, Stephan C, et al. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med 2013; 14(10): 633-8.
40. Tanaka H, Arai M, Tomoda Y, Wada T, Yago K, Satoh M. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients. J Pharm Pharm Sci 2013; 16(3): 405-13.
41. Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity. incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol 2014; 70(9): 1029-40.
42. Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-infected Subjects on Antiretroviral Therapy: the SATURNHIV Trial. Clin Infect Dis 2014; 59(8): 1148-56.
43. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial hiv-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014; 67(1): 52-8.